Evidence map›Paper›PMID 32632108›Full record

ArticleScientific data2020

A benchmark dataset of protein antigens for antigenicity measurement.

Tianyi Qiu, Jingxuan Qiu, Yiyan Yang, Lu Zhang, Tiantian Mao, Xiaoyan Zhang, Jianqing Xu, Zhiwei Cao

Abstract readDataset
In one paragraph

Article in Scientific data, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tianyi Qiu *Shanghai Public Health Clinical Center, Fudan University, Shanghai, 200032, China.
Jingxuan Qiu *School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Yiyan YangShanghai 10th People's Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Lu ZhangShanghai 10th People's Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Tiantian MaoShanghai 10th People's Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Xiaoyan ZhangShanghai Public Health Clinical Center, Fudan University, Shanghai, 200032, China.
Jianqing XuShanghai Public Health Clinical Center, Fudan University, Shanghai, 200032, China. xujianqing@shphc.org.cn.ORCID http://orcid.org/0000-0003-0896-9273
Zhiwei CaoShanghai 10th People's Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China. zwcao@tongji.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 31900483
6 · The paper itself

Abstract

Antigenicity measurement plays a fundamental role in vaccine design, which requires antigen selection from a large number of mutants. To augment traditional cross-reactivity experiments, computational approaches for predicting the antigenic distance between multiple protein antigens are highly valuable. The performance of in silico models relies heavily on large-scale benchmark datasets, which are scattered among public databases and published articles or reports. Here, we present the first benchmark dataset of protein antigens with experimental evidence to guide in silico antigenicity calculations. This dataset includes (1) standard haemagglutination-inhibition (HI) tests for 3,867 influenza A/H3N2 strain pairs, (2) standard HI tests for 559 influenza virus B strain pairs, and (3) neutralization titres derived from 1,073 Dengue virus strain pairs. All of these datasets were collated and annotated with experimentally validated antigenicity relationships as well as sequence information for the corresponding protein antigens. We anticipate that this work will provide a benchmark dataset for in silico antigenicity prediction that could be further used to assist in epidemic surveillance and therapeutic vaccine design for viruses with variable antigenicity.

Indexed as

Antigenic VariationAntigensAntigens, ViralDengue VirusHemagglutination Inhibition TestsInfluenza A Virus, H3N2 SubtypeInfluenza B virusNeutralization TestsAntigensAntigens, Viral

Identifiers

PMID32632108
PMCPMC7338539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.